Secondary Analysis of a Randomized Clinical Trial of Naltrexone Among Women Living With HIV: Correlations Between Reductions in Self-Reported Alcohol Use and Changes in Phosphatidylethanol.

Veronica L Richards, Ruba Sajdeya, Karina Villalba, Yan Wang, Vaughn Bryant, Babette Brumback, Kendall Bryant, Judith A Hahn, Robert L Cook
Author Information
  1. Veronica L Richards: From the, Department of Epidemiology, (VLR, RS, YW, VB, RLC), University of Florida, Gainesville, Florida. ORCID
  2. Ruba Sajdeya: From the, Department of Epidemiology, (VLR, RS, YW, VB, RLC), University of Florida, Gainesville, Florida.
  3. Karina Villalba: Robert Stempel College of Public Health and Social Work, (KV), Florida International University, Miami, Florida.
  4. Yan Wang: From the, Department of Epidemiology, (VLR, RS, YW, VB, RLC), University of Florida, Gainesville, Florida. ORCID
  5. Vaughn Bryant: From the, Department of Epidemiology, (VLR, RS, YW, VB, RLC), University of Florida, Gainesville, Florida. ORCID
  6. Babette Brumback: Department of Biostatistics, (BB), University of Florida, Gainesville, Florida.
  7. Kendall Bryant: National Institute on Alcohol Abuse and Alcoholism, (KB), Bethesda, Maryland.
  8. Judith A Hahn: Department of Medicine, (JAH), University of California, San Francisco, California. ORCID
  9. Robert L Cook: From the, Department of Epidemiology, (VLR, RS, YW, VB, RLC), University of Florida, Gainesville, Florida.

Abstract

BACKGROUND: Direct biomarkers such as Phosphatidylethanol (PEth) have the capability to detect heavy alcohol use, but it is unclear how strongly self-reported reduction in alcohol use correlates with reduction in PEth. We sought to explore the strength of correlation between reductions in self-reported alcohol use and change in PEth among a sample of women living with HIV (WLWH) who participated in a clinical trial to reduce heavy alcohol use. We also sought to determine whether this correlation was stronger in women with lower body mass index (BMI) and women without an alcohol use disorder (AUD).
METHODS: 81 WLWH (mean age = 48.7, 80% Black) engaging in a randomized trial of naltrexone versus placebo with a positive baseline PEth (���8 ng/ml), and alcohol use data at baseline, 2, and 7 months were included in this analysis. Spearman correlation coefficients were compared to measure the correlation between baseline PEth and number of drinks per week by demographic, biological, and alcohol use factors. Mini-International Neuropsychiatric Interview was used to screen for AUD. Further analyses were stratified by BMI and AUD. Spearman correlation coefficients were calculated for the change in PEth and the change in number of drinks per week over 7 months, including 3 time-points: baseline, 2, and 7 months.
RESULTS: At baseline, the correlation between baseline PEth and the number of drinks per week was significantly stronger for those with a BMI ���25 compared to those with a BMI > 25 (r = 0.66; r = 0.26, respectively). Similarly, the correlation between baseline PEth and number of drinks was stronger for those who did not screen positive for AUD compared with those who did (r = 0.66; r = 0.25, respectively). When stratifying by BMI, a low-to-moderate correlation (r = 0.32, p = 0.02) was present for persons with a BMI > 25; when stratifying by AUD, a moderate correlation (r = 0.50, p < 0.01) was present for persons without an AUD between 0 and 2 months only.
CONCLUSIONS: In this sample of WLWH, BMI and AUD affected the strength of correlation between PEth and drinks per week. Future work examining changes in PEth over time in broader populations is needed, particularly to understand the sex differences in PEth levels.

Keywords

References

  1. Alcohol Clin Exp Res. 2014 Jun;38(6):1706-11 [PMID: 24848614]
  2. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57 [PMID: 9881538]
  3. Addiction. 2016 Feb;111(2):272-9 [PMID: 26381193]
  4. Alcohol Alcohol. 2006 Jul-Aug;41(4):431-7 [PMID: 16624837]
  5. Drug Alcohol Depend. 2017 Sep 1;178:80-86 [PMID: 28645063]
  6. Alcohol Clin Exp Res. 2019 Aug;43(8):1790-1800 [PMID: 31373701]
  7. J Appl Lab Med. 2018 May 1;2(6):880-892 [PMID: 33636821]
  8. Alcohol Clin Exp Res. 2018 Jan;42(1):128-134 [PMID: 29080351]
  9. Curr Opin Clin Nutr Metab Care. 2008 Jan;11(1):21-6 [PMID: 18090653]
  10. Int J Mol Sci. 2012 Nov 13;13(11):14788-812 [PMID: 23203094]
  11. J Forensic Sci. 2018 Nov;63(6):1634-1640 [PMID: 30005144]
  12. Forensic Sci Int. 2007 Oct 25;172(2-3):119-24 [PMID: 17306943]
  13. Alcohol Clin Exp Res. 2010 Jun;34(6):955-67 [PMID: 20374219]
  14. Alcohol Clin Exp Res. 2015 Aug;39(8):1518-27 [PMID: 26148140]
  15. Alcohol Clin Exp Res. 2020 Jun;44(6):1261-1272 [PMID: 32441814]
  16. Addict Biol. 2010 Jan;15(1):88-95 [PMID: 20002024]
  17. Alcohol Clin Exp Res. 2016 Jun;40(6):1228-34 [PMID: 27130527]
  18. Alcohol Clin Exp Res. 2018 May;42(5):851-860 [PMID: 29505133]
  19. Alcohol Clin Exp Res. 2016 Aug;40(8):1779-87 [PMID: 27426424]
  20. CMAJ. 2018 Nov 19;190(46):E1350-E1360 [PMID: 30455270]
  21. Hepatology. 2007 Dec;46(6):2032-9 [PMID: 18046720]
  22. Obes Surg. 2018 Aug;28(8):2354-2360 [PMID: 29500677]
  23. Popul Health Metr. 2017 Feb 10;15(1):4 [PMID: 28183309]
  24. Subst Abuse Treat Prev Policy. 2019 Nov 14;14(1):52 [PMID: 31727086]
  25. Alcohol Alcohol. 2019 Dec 1;54(6):567-573 [PMID: 31529064]
  26. Alcohol Alcohol. 2015 Sep;50(5):519-25 [PMID: 26051989]
  27. Mol Psychiatry. 2017 Sep;22(9):1359-1367 [PMID: 28485404]
  28. Forensic Sci Int. 2009 Jul 1;188(1-3):52-6 [PMID: 19395207]
  29. Addict Biol. 2007 Mar;12(1):81-4 [PMID: 17407500]
  30. Alcohol Clin Exp Res. 2012 May;36(5):854-62 [PMID: 22150449]
  31. Alcohol Alcohol. 2019 May 1;54(3):251-257 [PMID: 30968936]
  32. Alcohol Clin Exp Res. 2016 Nov;40(11):2292-2295 [PMID: 27716960]
  33. Alcohol Alcohol. 2009 Sep-Oct;44(5):464-7 [PMID: 19535495]
  34. AIDS Behav. 2017 Jul;21(7):1938-1949 [PMID: 28421353]
  35. Alcohol Alcohol. 2015 Jul;50(4):399-406 [PMID: 25882743]
  36. World J Gastroenterol. 2018 Nov 14;24(42):4728-4737 [PMID: 30479460]
  37. Commun Stat Simul Comput. 2017;46(10):7924-7941 [PMID: 29962657]
  38. Alcohol Clin Exp Res. 2015 Nov;39(11):2200-8 [PMID: 26503066]
  39. J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):135-143 [PMID: 29112041]

Grants

  1. K24 AA022586/NIAAA NIH HHS
  2. T32 AA025877/NIAAA NIH HHS
  3. U01 AA020797/NIAAA NIH HHS

MeSH Term

Adult
Alcohol Deterrents
Alcohol Drinking
Female
Florida
Glycerophospholipids
HIV Infections
Humans
Middle Aged
Naltrexone
Self Report

Chemicals

Alcohol Deterrents
Glycerophospholipids
phosphatidylethanol
Naltrexone

Word Cloud

Created with Highcharts 10.0.0PEthcorrelationalcoholuseAUDbaseliner = 0BMIdrinksnumberperweekchangewomenHIVWLWHstronger7 monthscomparedheavyself-reportedreductionsoughtstrengthsampletrialwithoutpositive2SpearmancoefficientsscreenBMI > 2566respectivelystratifyingpresentpersonsWomenLivingAlcoholPhosphatidylethanolBACKGROUND:DirectbiomarkersphosphatidylethanolcapabilitydetectunclearstronglycorrelatesexplorereductionsamonglivingparticipatedclinicalreducealsodeterminewhetherlowerbodymassindexdisorderMETHODS:81meanage = 48780%Blackengagingrandomizednaltrexoneversusplacebo���8 ng/mldataincludedanalysismeasuredemographicbiologicalfactorsMini-InternationalNeuropsychiatricInterviewusedanalysesstratifiedcalculatedincluding3time-points:RESULTS:significantly���2526Similarly25low-to-moderate32p = 002moderate50p < 00102 monthsonlyCONCLUSIONS:affectedFutureworkexaminingchangestimebroaderpopulationsneededparticularlyunderstandsexdifferenceslevelsSecondaryAnalysisRandomizedClinicalTrialNaltrexoneAmongHIV:CorrelationsReductionsSelf-ReportedUseChangesHeavyDrinking

Similar Articles

Cited By (2)